BioSpace News Archive

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its third quarter 2020 financial results after market close on Tuesday, November 10, 2020

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2020 and updated its full year 2020 guidance

First of multiple anticipated milestone payments related to the development of Oral KORSUVA™

Amgen (NASDAQ:AMGN) today announced that it has completed trial design discussions through two Complex Innovative Trial Designs (CID) Pilot Program meetings with the U.S. Food and Drug Administration (FDA) for its planned Phase 2 efficacy and safety trial for efavaleukin alfa (formerly known as AMG 592),

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today reported financial results for its third quarter ended September 30, 2020.

Business Highlights - Revenue of $1.605 billion, increasing 6.7%; organic growth of 5.4% - Net loss of $42.2 million; Adjusted EBITDA $285.6 million, expansion of 112 basis points - Diluted GAAP loss per share of $0.10; adjusted EPS $0.24, increase of 63.4% - YTD Operating Cash Flow $623.8 million, increase of 133.6%; YTD Free Cash Flow $582.4 million, increase of 156% - Adjusted net leverage of 4.2x from 4.6x at December 31, 2019

Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab™, today announced that the Company’s management will present or participate in panel discussions at the following upcoming virtual investor conferences:

Invacare Corporation (“Invacare”)(NYSE: IVC), a leading manufacturer and distributor of medical equipment used in non-acute care settings, has been recognized by HME Business magazine in multiple product categories for outstanding product development achievements

Abeona Therapeutics Inc., a fully-integrated leader in gene and cell therapy, announced that Michael Amoroso, Senior Vice President and Chief Commercial Officer at Abeona, has been promoted to Chief Operating Officer and will serve as the Company’s principal executive and operating officer, effective November 1, 2020.

The financing includes a $235 million equity investment co-led by Highland Capital Management and Coatue; Sixth Street participates in equity round and provides $75 million in debt financing